RxDoctor Payments Data

Robert Schreiman, MD

Family Medicine · Tustin, CANPI 1871605196

Payments from drug & device makers

$19,944in general payments, 2019–2025

Across 199 payments — averaging $100.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$14K
  • Acadia Pharmaceuticals Inc$1K
  • Avanir Pharmaceuticals, Inc.$453
  • SK Life Science, Inc.$417
  • CMP Pharma, Inc.$398
  • Teva Pharmaceuticals USA, Inc.$336
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$5,558100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,944 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$277,604
Medicare patients
394
Services billed
2,477

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban401$157,588
JardianceEmpagliflozin135$66,426
XareltoRivaroxaban174$60,548
TrulicityDulaglutide24$24,657
FarxigaDapagliflozin Propanediol71$24,508
RexultiBrexpiprazole37$22,059
JanuviaSitagliptin Phosphate63$18,772
MyrbetriqMirabegron39$14,175
Memantine Hcl269$13,079
DapagliflozinDapagliflozin Propanediol40$12,436
Memantine Hcl ErMemantine Hcl116$12,269
Atorvastatin Calcium838$10,689
MultaqDronedarone Hcl11$10,010
Levetiracetam194$9,222
EntrestoSacubitril/Valsartan17$8,602

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$68$157,588401 claims
Johnson & JohnsonXarelto$99$60,548174 claims
AstraZenecaFarxiga, Brilinta$60$30,27783 claims
Lilly USA, LLCTrulicity, Olanzapine$180$29,279152 claims
MerckJanuvia, Janumet Xr$69$25,74179 claims
Otsuka America Pharmaceutical, Inc.Rexulti$295$22,05937 claims
Astellas Pharma US IncMyrbetriq$260$14,17539 claims
GSKBreo Ellipta, Incruse Ellipta$75$11,21029 claims
NovartisEntresto$157$8,60217 claims
AbbVieLinzess$57$6,98412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Tustin

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →